Asahi Kasei Corporation
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Latest news
All AHKSF news ›Japan’s new ambassador visits Port Colborne to tour Asahi Kasei construction site
Masashi Nakagome, Japan’s ambassador to Canada, visited the lakeside city and sat down in a private meeting with Mayor Bill Steele. Masashi Nakagome, Japan’s ambassador to Canada, and Port Colborne Mayor Bill Steele pose in front of their…
Port Colborne museum welcomes Asahi Kasei’s arrival with Japanese cultural exhibition at Roselawn Centre
Port Colborne Historical and Marine Museum is presenting a special collection on loan from The Japan Foundation, Toronto. Port Colborne Historical and Marine Museum is sharing a piece of Japanese culture with a new exhibition at Roselawn…
Tosoh to acquire Asahi Kasei’s stake in HDI monomer JV, taking full ownership
October 14, 2026 | By Mary Bailey Tosoh Corp. (Tokyo) has decided to acquire all shares (50%) of Nanyo Kasei Co., Ltd. (Tokyo), a joint venture with Asahi Kasei Corp. (Tokyo). The deal will make Nanyo Kasei a wholly owned subsidiary of…
Goldman Sachs downgrades Asahi Kasei (AHKSF) to a Hold
The Globe and Mail Goldman Sachs analyst downgraded Asahi Kasei to a Hold on October 8 and set a price target of Yen2,010.00. The company’s shares closed last Thursday at Yen1,650.50. The word on The Street in general, suggests a Moderate…
Asahi Kasei Acquisition Pays Off With FDA Approval for Novel Herpes Drug
Asahi Kasei’s Hovilpri is now approved for treating lesions caused by herpes simplex virus infection. This daily pill came from the $919 million acquisition of AiCuris Anti-Infective Cures. Patients with lesions caused by herpes simplex…
Aicuris acquisition delivers new drug for Asahi Kasei
Asahi Kasei's $920 million takeover of German biotech Aicuris in April has paid off with FDA approval for the herpes simplex virus (HSV) drug at the heart of the deal. The oral drug, called Hovilpri (pritelivir), has been cleared for…
US FDA approves Asahi Kasei's drug for persistent herpes infections
Published On Oct 12, 2026 at 07:45 AM IST Find this Comment Offensive? Join the community of 2M+ industry professionals. All about ETPharma industry right on your smartphone!
Asahi Kasei Wins USFDA Approval for Oral Antiviral Hovilpri (Pritelivir) for Refractory Herpes
Bengaluru: The US FDA on Friday approved Japan's Asahi Kasei's drug for persistent herpes simplex virus sores in certain patients with weakened immune systems who have not responded to available antiviral treatments. The oral drug, called…
Asahi Kasei Therapeutics Announces FDA Approval of HOVILPRI® (pritelivir) Tablets for Mucocutaneous HSV Lesions Refractory (With or Without Resistance) to Standard Antiviral Treatment in Immunocompromised Adults
HOVILPRI is expected to be available in the United States before the end of 2026. U.S. Healthcare providers can learn more about HOVILPRI at www.hovilprihcp.com. About the PRIOH-1 Trial About Herpes Simplex Virus INDICATION AND IMPORTANT…
Asahi Kasei wins FDA approval for HOVILPRI in refractory HSV
The oral drug's label covers immunocompromised adults whose lesions failed standard antivirals, with U.S. availability expected before the end of 2026. An oral treatment for refractory herpes simplex lesions won U.S. approval on Friday as…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
batteriesnews.com1
-
biobuzz.io1
-
chemengonline.com1
-
finance.biggo.com1
-
genengnews.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 12 articles, not a forecast.